follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
third-quart world-wide sale billion increas sale increas exclud
impact foreign exchang growth driven oncolog human health vaccin
keytruda sale grew billion exclud impact foreign exchang sale grew
human health vaccin sale grew billion exclud impact foreign exchang sale grew
third-quart ep increas third-quart non- ep
increas
compani narrow rais full-year revenu rang billion billion
includ neg impact foreign exchang approxim
compani narrow reduc full-year ep rang narrow
rais full-year non-gaap ep rang includ neg impact
foreign exchang approxim
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result third quarter
achiev anoth quarter strong revenu earn growth continu realiz benefit
sustain invest research develop focu commerci execut said kenneth frazier
chairman chief execut offic merck confid invest make allow us
convert cutting-edg scienc medicin vaccin great benefit patient valu sharehold
million except ep amount
non-gaap net incom exclud certain
non-gaap ep exclud certain
gener accept account principl earn per share assum dilut ep third
quarter non-gaap ep third quarter exclud million charg
acquisit peloton therapeut inc peloton million pre-tax intang asset impair charg
acquisition- divestiture-rel cost restructur cost certain item year-to-d result
found attach tabl
merck continu advanc develop program keytruda pembrolizumab compani
therapi lynparza olaparib parp inhibitor co-develop co-commerci astrazeneca
lenvima lenvatinib mesyl oral avail
inhibitor co-develop co-
commerci eisai co ltd eisai
merck announc follow regulatori mileston keytruda
approv china monotherapi first-lin treatment patient local advanc metastat non-
small cell lung cancer nsclc whose tumor express base overal surviv result
trial keytruda first therapi approv china monotherapi
combin chemotherapi first-lin treatment nsclc
approv europ combin axitinib first-lin treatment advanc renal cell carcinoma rcc
across intern metastat rcc databas consortium imdc risk group base overal surviv result
trial
approv unit state food drug administr fda monotherapi treatment
patient recurr local advanc metastat squamou cell carcinoma esophagu whose tumor
express combin posit score diseas progress one prior line
therapi base result trial
adopt posit opinion committe medicin product human use chmp european
medicin agenc ema two regimen keytruda monotherapi combin platinum
fluorouracil chemotherapi first-lin treatment metastat unresect recurr head neck
squamou cell carcinoma hnscc adult whose tumor express base data
trial
file accept fda supplement biolog licens applic sbla seek use keytruda
treatment patient recurr and/or metastat cutan squamou cell carcinoma cscc
curabl surgeri radiat fda set pdufa date june
merck present result pivot neoadjuvant/adjuv phase trial patient early-
stage triple-neg breast cancer tnbc first random trial therapi set
european societi medic oncolog esmo congress interim result neoadjuv phase
show combin keytruda plu chemotherapi result statist signific increas
patholog complet respons versu chemotherapi patient early-stag tnbc
merck present first-tim result pool analysi three random keynot studi
cohort evalu keytruda combin chemotherapi
advanc nsclc combin regimen demonstr improv overal surviv among
newli diagnos patient whose tumor express data present iaslc world
confer lung cancer
merck astrazeneca present result phase profound trial patient metastat castration-
resist prostat cancer mcrpc mutat homolog recombin repair hrr gene
whose diseas progress prior treatment new hormon agent treatment esmo
congress studi lynparza improv radiograph progression-fre surviv versu standard care
atm-mut tumor well reduc risk diseas progress death tumor
mutat gene associ hrr
merck astrazeneca also present result phase trial esmo congress
lynparza ad bevacizumab reduc risk diseas progress death first-lin
mainten set patient advanc ovarian cancer complet partial respons platinum-
base chemotherapi bevacizumab
merck astrazeneca receiv file submiss accept fda ema use lynparza
brcam pancreat cancer base result phase polo trial decis fda expect
fourth quarter ema second half
merck eisai announc acceler fda approv combin keytruda lenvima patient
certain type endometri carcinoma base data mark first
approv combin first time therapi approv combin kinas
inhibitor advanc endometri carcinoma unit state approv grant fda real-
time oncolog review pilot program well new fda-initi program fda partner
australian canadian regulatori bodi review applic allow simultan decis
three countri
merck announc fda approv expand use pifeltro doravirin combin
antiretrovir agent delstrigo doravirine/lamivudine/tenofovir disoproxil fumar treatment
adult patient infect virolog suppress rna less copi per ml
stabl antiretrovir regimen histori treatment failur
merck announc fda accept new drug applic nda dificid fidaxomicin oral suspens
supplement nda snda use dificid tablet oral suspens treatment clostridium
difficil infect children age six month older fda set pdufa date jan
merck announc pivot phase restore-imi trial evalu recarbrio imipenem cilastatin
relebactam use adult hospital-acquir bacteri pneumonia ventilator-associ bacteri
pneumonia habp/vabp met primari endpoint
merck announc ema chmp adopt posit opinion recommend condit market
author compani investig vaccin brand name ervebo rvsvg-zebov-gp live
protect ebola viru diseas caus zair ebola viru well fda accept prioriti
review biolog licens applic bla fda set pdufa date march
follow tabl reflect sale compani top pharmaceut product well sale anim health
million
proquad m-m-r ii
third-quart pharmaceut sale billion increas compar third quarter
exclud unfavor effect foreign exchang sale grew third quarter increas driven
primarili growth oncolog vaccin partial off-set on-going impact loss market exclus
sever product well lower sale januvia sitagliptin janumet sitagliptin metformin
pharmaceut sale repres total sale quarter perform intern
market led china pharmaceut sale million repres growth compar
third quarter driven vaccin primarili gardasil papillomaviru quadrival type
vaccin recombin gardasil human papillomaviru vaccin recombin
oncolog exclud unfavor effect foreign exchang pharmaceut sale china grew
growth oncolog larg driven billion increas sale keytruda billion reflect
strong momentum nsclc indic well continu uptak indic includ recent
launch rcc adjuv melanoma indic along growth lynparza lenvima
growth vaccin reflect higher sale gardasil gardasil vaccin prevent certain cancer
diseas caus hpv primarili due higher demand asia pacif particularli china also contribut
sale growth higher demand europ driven primarili increas vaccin rate boy girl
well higher price demand unit state partial off-set public sector buy pattern
octob compani borrow dose gardasil center diseas control
prevent cdc pediatr vaccin stockpil reduc gardasil sale fourth quarter
approxim million dose alloc support routin vaccin unit state
allow compani manufactur dose part world includ region
growth pediatr vaccin driven varivax varicella viru vaccin live vaccin help prevent
chickenpox proquad measl mump rubella varicella viru vaccin live combin vaccin
help protect measl mump rubella varicella reflect higher demand price unit state
higher demand europ latin america
perform hospit acut care reflect higher demand global particularli unit state bridion
sugammadex inject mg/ml medicin revers neuromuscular blockad induc rocuronium
bromid vecuronium bromid adult undergo surgeri on-going launch prevymi letermovir
medicin prophylaxi prevent cytomegaloviru cmv infect diseas adult cmv-seroposit
recipi allogen hematopoiet stem cell transplant
pharmaceut sale growth quarter partial off-set on-going impact loss market
exclus invanz ertapenem sodium zetia ezetimib vytorin ezetimibe/simvastatin cubicin
daptomycin remicad infliximab addit declin sale januvia janumet reflect
continu price pressur unit state off-set higher demand global
anim sale total billion third quarter increas compar third
quarter exclud unfavor effect foreign exchang anim health sale grew growth
third quarter primarili driven livestock due product acquir antelliq acquisit along
growth companion anim product driven larg higher sale bravecto fluralan line
product parasit control
anim segment profit million third quarter increas compar
million third quarter
third-quart expens ep relat inform
gaap expens ep relat inform
gross margin third quarter compar third quarter increas
gross margin third quarter reflect favor impact charg relat
termin collabor agreement samsung bioepi co ltd product mix partial off-set higher
acquisition- divestiture-rel cost includ impact intang asset impair charg higher
amort unfavor manufactur varianc higher amort
collabor higher restructur cost well manufactur facil start-up cost
sell gener administr expens billion third quarter increas compar
third quarter increas primarili reflect higher promot administr cost primarili
support strateg brand higher acquisition- divestiture-rel cost partial off-set favor
effect foreign exchang
research develop expens billion third quarter increas
compar third quarter increas driven primarili million charg record
third quarter acquisit peloton coupl higher expens relat clinic develop
increas invest discoveri research earli drug develop
incom expens net million expens third quarter compar million
incom third quarter primarili reflect lower incom invest equiti secur higher
effect incom tax rate third quarter includ unfavor impact charg
acquisit peloton tax benefit recogn favor impact product mix
gaap ep third quarter compar third quarter
non-gaap expens ep relat inform
non-gaap gross margin third quarter compar third quarter
decreas non-gaap gross margin primarili reflect higher amort unfavor manufactur
varianc higher amort intang asset relat collabor well manufactur facil start-up
non-gaap sell gener administr expens billion third quarter increas
compar third quarter increas reflect higher promot administr cost primarili
support strateg brand partial off-set favor effect foreign exchang
non-gaap expens billion third quarter increas compar third quarter
increas primarili reflect higher expens relat clinic develop increas invest
discoveri research earli drug develop
non-gaap incom expens net million expens third quarter compar
million incom third quarter primarili reflect lower incom invest equiti secur
higher net interest expens
non-gaap effect incom tax rate third quarter reflect favor impact
non-gaap ep third quarter compar third quarter
merck narrow rais full-year revenu rang billion billion includ
impact gardasil stockpil borrow note neg impact foreign exchang
approxim mid-octob exchang rate
merck reduc expect full-year effect tax rate approxim expect full-year non-
effect tax rate approxim reduct primarili attribut favor product mix
merck narrow reduc full-year ep rang chang
ep rang primarili reflect impact intang asset impair charg note merck
narrow rais full-year non-gaap ep rang includ neg
impact foreign exchang approxim mid-octob exchang rate non-gaap rang exclud
acquisition- divestiture-rel cost cost relat restructur program net benefit settlement
certain feder incom tax matter charg acquisit peloton certain item
expect full-year effect tax rate reflect net favor impact approxim one
percentag point item
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
merck compani inc american pharmaceut compani one largest pharmaceut compani
world compani establish unit state subsidiari german compani merck
found merck famili global healthcar compani histori
work make differ compani known merck unit state canada everywher els
known msd base kenilworth oper countri
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
well-balanc divers foundat abbott strategi success four major busi roughli
equal size balanc extend across geographi payer constantli shape portfolio ensur
right market success isnt reliant singl therapi technolog countri
payer approxim percent sale direct consum patient make abbott one
consumer-fac healthcar compani world
abbott one global healthcar compani world percent revenu gener market
outsid unit state percent revenu gener faster-grow geographi healthcar
spend outpac growth gross domest product
abbott well posit grow major trend underli busi broader global
environ addit growth develop economi global middl class vastli
expand market abil help peopl around world relat equal power trend drive
busi age global popul abbott major busi well- align relev
leader serv trend across multipl market
abbott intend lead scientif commerci market compet abbott hold
variou leadership posit across mani busi segment across multipl geographi requir
presenc market meet local healthcar need prefer mani key stakehold includ
hospit physician pharmaci consum
strength add fundament advantag offer investor consist reliabl perform
foundat abbott built strong built last succeed deliv superior
innov product growth consist reliabl
compani take toughest health challeng treat diseasesw aim make
remark impact peopl live highli focus research-driven biopharmaceut
employe scientist research commun manufactur specialist regulatori expert
locat around globe come new approach address today health issuesfrom life-
threaten ill chronic condit
target specif difficult-to-cur diseas leverag core expertis advanc scienc
constantli work creat solut go beyond treat ill posit impact patient
live societiesand scienc
see futur full possibl health reach patient live improv
principl foundat
purpos profound path clear embrac respons make remark impact
peopl live innov medicin solut creat togeth driven compass
peopl commit innov inclus servic commun uncompromis integr
heart everyth
oper one team care deepli patient famili employe commun
strive alway right thing pursu highest standard qualiti complianc safeti
perform everyth invest innov relentlessli tackl unmet need creat new medicin
healthcar approach healthier world
global employe embrac divers background perspect treat everyon equal digniti
respect allow us achiev best proudli part serv support commun protect
environ make last impact felt within healthcar beyond
easi persever achiev inspir hope transform liveseveri singl
inspir hope transform live everi day make decis base deep care compass
peopl deliv last impact patient famili employe commun
act integr
strive alway right thing uncompromis integr heart everyth pursu
highest standard qualiti complianc safeti perform
innov relentlessli everyth tackl unmet need invest discoveri develop
new medicin healthcar approach healthier world
treat everyon equal digniti respect around world employe embrac divers background
perspect allow us achiev best
serv commun
proud serv support commun part protect environ make
remark impact felt within healthcar beyond
may found root run deep becam separ compani
abbott though share common legaci strong prospect futur success
name repres connect past futur becam compani form
new kind enterprisea biopharmaceut compani blend stabil global scale resourc
commerci capabl pharmaceut compani focu cultur biotech
today employe around world focu deliv transform medicin therapi
allergan plc nyse agn headquart dublin ireland global pharmaceut leader focus
develop manufactur commerci brand pharmaceut devic biolog surgic regen
medicin product patient around world
allergan market portfolio lead brand best-in-class product primarili focus four key therapeut
area includ medic aesthet eye care central nervou system gastroenterolog part approach
deliv innov better patient care allergan built one broadest pharmaceut devic
research develop pipelin industri
colleagu commerci oper locat approxim countri allergan commit work
physician healthcar provid patient deliv innov meaning treatment help peopl
around world live longer healthier live everi day
one world largest pharmaceut servic compani serv unit state
canada select global market focu pharmaceut suppli channel servic
pharmaceut manufactur healthcar provid compani servic solut rang nich premium
logist pharmaceut packag reimburs pharmaceut consult servic scale
posit healthcar industri valu bring channel help busi continu
oper reach across globe pharmaceut distribut center three
specialti distribut center strateg locat throughout unit state current nine
distribut center canada recent acquisit world courier largest experienc
specialti logist compani servic expand includ network wholly-own iso offic
countri
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
belief core strategi innov highli differenti medicin provid larg clinic
benefit address seriou diseas medicin help patient also help reduc
social econom burden diseas societi today focus area high unmet medic need
leverag expertis strive solut improv health outcom dramat improv peopl live
biotechnolog innov sinc grown one world lead independ biotechnolog
compani reach million patient around world develop pipelin medicin
presenc approxim countri region world-wide innov medicin
reach million peopl fight seriou ill focu six therapeut area cardiovascular
diseas oncolog bone health neurosci nephrolog inflamm medicin typic address
diseas limit treatment option medicin provid viabl option
understand fundament biolog mechan diseas defin featur discoveri
research effortsand major contributor develop deep broad pipelin potenti new
medicin biolog first approach permit scientist first explor complex molecular pathway
diseas determin type medicin modal like deliv optim efficaci safeti
advanc human genet continu shed new light molecular root diseas
subsidiari decod genet global leader human genet power differenti greatli improv
identifi valid human diseas target
treatment million serious ill patient world-wide depend safe reliabl product biolog
medicin administ inject intraven world-wide leader biolog manufactur
outstand track record reliabl deliv high-qual medicin patient need
signific skill experi vigil commit critic help ensur qualiti biolog medicin
time new batch made robust qualiti control reliabl suppli medicin patient
everi bit import scientif innov
build advanc recombin dna molecular biolog count among earli pioneer
biotechnolog sinc scientist work develop novel therapi patient seriou
ill scientist character key biolog process led develop innov
first-in-class therapi help shape scientif world understand certain diseas process
engin new type therapeut platform compani could accomplish
deep commit build cultur embrac scienc innovationa cultur
continu shape today
amgen foundat seek advanc excel scienc educ inspir next gener
innov invest strengthen commun staff member live work date
foundat donat nearli million grant local region intern nonprofit organ
impact societi inspir innov way amgen foundat bring excit discoveri
scientist tomorrow sever signatur program includ amgen scholar amgen biotech experi
amgen teach inform visit www amgeninspir com
global science-l biopharmaceut busi innov medicin use million
purpos valu
purpos valu help explain exist hope accomplish behaviour valu
achiev goal promis brand stakehold
transform pipelin return growth result continu pipelin deliveri
commerci execut enter new stage journey focus enhanc innov
deliveri life-chang medicin contribut valu patient societi
fundament strategi clear focu innov scienc leadership three main therapi
area oncolog cardiovascular renal metabol respiratori diseas back global presenc
strength emerg market particularli china portfolio specialti primari care medicin
time world around us chang burden diseas increas respond
increas focu growth innov patient-centr technolog digit
data advanc cutting-edg scienc
reflect three strateg prioriti
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
manufactur market broad rang brand gener pharmaceut over-the-count over-the-counter
product medic devic contact lens intraocular lens ophthalm surgic equip aesthet
devic directli indirectli countri region includ unit state canada europ
middl east africa asia pacif latin america day product use million peopl
around world
diversifi portfolio product core focu follow area
global corpor headquart locat laval quebec canada headquart
bausch health serv follow geograph region
north america asia pacif latin america europ middl east africa region offer
differ focu distinct market market uniqu mix prescript brand over-the-count
over-the-counter product medic devic
baxter touch live million peopl around world everi day product therapi found
throughout hospit clinic er pharmaci icu well advanc patient
care home inc fortun american health care compani headquart
critic intersect save sustain live
determin uniqu posit realiz greatest opportun transform global healthcar year
baxter touch million live everi day product servic essenti build block healthcar
baxter mission save sustain live six global busi renal medic deliveri
pharmaceut clinic nutrit advanc surgeri acut therapi focus transform innov
deliv smarter person care patient provid everi day mission save sustain live
forefront strive meet goal top-quartil perform object acceler growth
expand baxter impact across healthcar spectrum support evolut new product pipelin
bristol-my squibb differenti compani led uniqu biopharma strategi leverag reach
resourc major pharma compani pair entrepreneuri spirit agil biotech firm work
everi day deliv innov medicin patient seriou life-threaten diseas
day employe around world work togeth patientsit drive everyth focus
help million patient around world diseas area oncolog cardiovascular immunosci
fibrosi research develop organis built sustain pipelin potenti
therapi activ partner access extern innov broaden acceler work
global citizen work sustain respons seek give back bristol-my squibb
foundat promot health equiti strive improv health outcom popul disproportion
affect seriou diseas condit give new hope world vulner peopl
lilli found colonel eli lilli man commit creat high-qual medicin met real need
era unreli elixir peddl question charact charg gener employe
follow take find make better better
year later remain commit vision everi aspect busi peopl
serv start take medicin extend health care profession employe
commun live eli lilli compani american pharmaceut compani headquart
indianapoli indiana offic countri product sold approxim countri
three long establish core valu guid lilli
integr conduct busi consist applic law honest deal
custom employe sharehold partner supplier competitor commun
excel pursu pharmaceut innov provid high qualiti product strive deliv superior
respect peopl maintain environ built mutual respect open individu integr
respect peopl includ concern peopl touch touch compani custom
employe sharehold partner supplier commun
lilli glanc
heritag year strong compani found may
headquart locat indianapoli indiana
employe engag research develop
clinic research conduct countri
research develop facil locat countri
manufactur plant locat countri
product market countri
june
dollar million except per-shar data
net incom report
earn per share report
 percentag sale
employe engag activ
percentag total workforc
pharmaceut
averag cost discov develop new drug billion
averag length time discoveri patient year
consid founder industri genentech member roch group deliv
promis biotechnolog year
genentech biotechnolog compani dedic pursu groundbreak scienc discov develop
medicin peopl seriou life-threaten diseas transform discoveri includ first
target antibodi cancer first medicin primari progress multipl sclerosi
member roch group
genentech becam member roch group march part merger agreement roch
genentech combin pharmaceut oper unit state genentech south san francisco
campu serv headquart roch pharmaceut oper unit state genentech
research earli develop oper independ center within roch
science-l global healthcar compani special purpos help peopl feel better live
glaxosmithklin plc form result merger glaxo wellcom plc smithklin
beecham plc although histori trace back year london plough court pharmaci
goal one world innov best perform trust healthcar compani
strategi bring differenti high-qual need healthcar product mani peopl possibl
three global busi scientif technic know-how talent peopl
valu expect heart everyth form import part cultur
valu patient focu transpar respect integr
expect courag account develop teamwork
johnson johnson believ good health foundat vibrant live thrive commun forward
progress that year aim keep peopl well everi age everi stage
life today world largest broadli base healthcar compani commit use reach
size good strive improv access afford creat healthier commun put healthi
mind bodi environ within reach everyon everywher
everi day employe across world blend heart scienc ingenu
profoundli chang trajectori health human
johnson johnson incorpor state new jersey
era unpreced complex healthcar patient care mani
organ deliv care need get much healthier
vision improv care everi set one product one partner one patient time
make happen everi day touch virtual everi aspect healthcar
partner biopharma compani care provid pharmaci manufactur govern other
deliv right medicin medic product healthcar servic patient need need
safe cost-effect
unit icar valu employe work togeth everi day make better care possibl patient
around globe
global healthcar compani histori work make differ
make differ live peopl global innov medicin vaccin anim health
product commit premier research-intens biopharmaceut compani dedic
provid lead innov solut today futur
discov develop provid innov product servic save improv live around world
sinc research help find new way treat prevent ill discoveri
vitamin first measl vaccin cold remedi antacid first statin treat high cholesterol
scientist also help develop mani product improv anim health includ vaccin antibiot
today premier research-intens biopharmaceut compani focus make import scientif
advanc within hepat hiv diabet immuno-oncolog
proud past enthusiast futur aim creat healthier brighter futur
peopl around world
novarti creat merger ciba-geigi sandoz novarti predecessor compani
trace root back year rich histori develop innov product
purpos reimagin medicin improv extend peopl live use innov scienc
technolog address societi challeng healthcar issu discov develop breakthrough
treatment find new way deliv mani peopl possibl also aim reward
invest money time idea compani
strategi build lead focus medicin compani power advanc therapi platform data
implement strategi five prioriti shape futur help us continu creat valu
compani sharehold societi
unleash power peopl
transform cultur ensur peopl fulli appli talent energi creat
organ peopl inspir curiou unboss
pursuit transform treatment challeng medic paradigm explor possibl cure diseas
interven earlier chronic ill find way dramat improv qualiti life
rethink work embrac agil team build better product compani free
resourc invest innov help boost return
go big data digit
aim spark digit revolut novarti embrac digit technolog advanc analyt artifici
intellig help drive innov improv effici
build trust societi
strive build trust societi effort oper high valu integr find new way
expand patient access treatment
novo nordisk drive chang defeat diabet seriou chronic condit
novo nordisk global healthcar compani year innov leadership diabet care
heritag given us experi capabl also enabl us help peopl defeat seriou chronic
condit rare bleed disord growth hormon relat disord obes
headquart denmark novo nordisk employ approxim peopl countri market
product countri
chang world diabet year
behind novo nordisk know today lie excit stori goe back year began two small
danish compani nordisk insulinlaboratorium novo terapeutisk laboratorium found
respect two compani start product revolutionari new drug insulin
discov two canadian scientist
build past look futur
sinc earliest day nordisk novo focu develop product benefit peopl
diabet compet intens one anoth compani develop two best field
last decid merg creat novo nordisk compani expand rapidli ever
sinc lead posit within diabet care rare bleed disord growth hormone-rel disord
today novo nordisk way show respons patient employe commun investor
futur continu build legaci left founder novo nordisk whatev take
chang diabet histori tell us done
start humbl begin year ago rural michigan today one largest
luther perrigo owner gener store apple-dri busi idea packag
distribut patent medicin household item countri store luther launch privat label concept
way enhanc custom loyalti addit cost offer imprint store name label
epsom salt sweet oil bay rum dozen wet dri good stock gener store
deep root manufactur excel
open first manufactur facil michigan sign first larg private-label
custom pave way convers re-packag home remedi manufactur
afford healthcar product
shift strateg direct drove growth next sever decad serv heritag
guid compani mission today
pfizer inc research-bas global biopharmaceut compani appli scienc global resourc
bring therapi peopl extend significantli improv live discoveri develop
manufactur healthcar product global portfolio includ medicin vaccin well mani
strategi root four strateg imper remain constant sinc began transform
improv pfizer abil innov biomed develop new gener high valu highli
differenti medicin vaccin
invest alloc resourc way creat greatest long-term return sharehold
earn societi respect gener breakthrough therapi improv access expand dialogu health
care act respons corpor citizen
build sustain cultur colleagu view owner gener new idea deal
problem straightforward way invest open candid convers work teammat
challeng opportun
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
regeneron acceler improv tradit drug develop process proprietari
velocisuit technolog velocimmun produc optim fully-human antibodi ambiti
research initi regeneron genet center conduct one largest genet
sequenc effort world
field human health undergo profound scientif technolog chang point way major
therapeut innov patient
sanofi innov dna mission har new technolog new way work find
healthcar solut around world research develop strategi innov view
three angl scienc technolog digit
adapt research develop model recent year build excel develop
improv product john reed took helm sanofi juli unveil next chapter
evolut sanofi strategi februari
refocus pipelin special care
continu effort build strong pipelin make full use capabl biolog multi-
target product new technolog platform
line ambit innov leader decid refocu specialti particular
oncolog immunolog rare diseas rare blood disord maintain commit vaccin
industrial-scal product medicin vaccin heart
today close peopl industri site around globe work produc high-qual
biolog pill deliveri system
invest billion year modern industri facil two-third goe biotechnolog tie
 strategi increasingli focus develop complex biolog medicin invest aim make
sanofi world leader bio-product
alongsid physic transform product facil toward bio-product factori also
connect factori use data power new approach manufactur factori tomorrow data
captur sensor manufactur process give us control product maxim output
also use data guarante highest qualiti standard biolog medicin manufactur biolog
complex process slightest alter cell cultur condit result differ finish product
potenti impact safeti efficaci
digit major opportun healthcar sector defin focus competit digit strategi
creat valu two way help us run busi better faster effici develop new
digit technolog offer promis speed clinic trial get medicin patient faster
sanofi soon connect factori equip sensor transmit data automat advanc
analyt suppli chain data enabl real-tim optim
engag interact physician varieti channel includ chat forum medic content-
share platform consum healthcar busi also roll target market capabl
global scale
develop new approach go beyond medicin non-pharmacolog solut medic
devic data servic combin treatment deliv better outcom patient especi
peopl live diabet
final digit transform pave way us make use real world data mean concret
dataextract sourc electron medic record insur applic form patient survey
better understand healthcar solut work outsid clinic trial environ
build strong global footprint size scale teva reaffirm commit place peopl
center strategi enabl mani possibl live better healthier day develop
produc market afford high qualiti gener drug well innov specialti pharmaceut
activ pharmaceut ingredi
simplifi unifi busi leverag scale global leader healthcar meet
need stakehold make good promis build sustain busi deliv valu
improv health million peopl world-wide
wake pride everi morn know enabl peopl live better day ensur
highest standard complianc busi integr everyth
fact figur
teva establish global headquart base israel
today portfolio medicin produc approxim billion tablet capsul
year manufactur facil
rank among lead pharmaceut compani world activ countri approxim
employe around world dedic mission
area focu
turn insight treatment
specialti medicin busi focus deliv innov solut patient provid via
medicin devic servic base core therapeut area central nervou system includ
pain migrain movement neurodegen disord respiratori ill
make healthcar access
gener medicin meet critic consum healthcar system need
extens product portfolio industri gener prescript us fill teva
product prescript uk germani
teva among top three gener compani market around world
strong research develop expertis
effici high-qual manufactur global scale
teva lead global supplier activ pharmaceut ingredi api essenti raw materi drug
corpor cultur care
teva employe know effort go beyond achiev busi result teva strive creat work
environ enrich profession person live
wide rang social benefit
develop train program
opportun volunt contribut local commun
biopharmaceut compani across america peopl go work everi day mission advanc
innov treatment cure make differ million patient live
commit ensur patient access medicin preserv strong economi support vibrant
research valuabl job also stand behind medicin creat valu provid
patient across health care system
new era medicin breakthrough scienc transform care approach treat
patient robust invest research develop biopharmaceut compani result
advanc discoveri unlik anyth weve seen applic genom develop person
medicin enabl physician tailor treatment uniqu need patient immunotherapi
har patient immun system fight variou condit includ cancer rare diseas
last decad alon biopharmaceut compani invest half trillion dollar invest
begin yield result open door entir new way tackl complex difficult
treat diseas time
progress see today revolution treat diseas save patient live improv qualiti life
public health across broad rang chronic rare condit new era medicin mani diseas
previous regard deadli manag potenti curabl today medicin
clinic develop around world across medicin pipelin clinic develop
potenti first-in-class treatment repres entir new approach treat diseas futur
never brighter research explor new frontier year ago may regard
scienc fiction transform patient live
new era medicin isnt good news healthit good news health care system societi
new innov medicin keep patient healthi hospit reduc need costli emerg
room visit hospit stay surgeri long-term care save money patient nation health
system look forward medicin best bet confront countri biggest health cost driver chronic
diseas condit cancer diabet heart diseas lead caus death disabl
unit state patient condit account health care spend iv continu
advanc treatment indispens address societi health econom challeng year
invest biopharmaceut innov improv save live also drive tremend contribut
american economi america role leader medic innov biopharmaceut
compani invest billion unit state industri america
industri support million job across countri employe across compani
go work everi day research develop new treatment cure patient occur even face
continu setback develop timelin extens cost high rate scientif
new medicin transform care patient fight debilit diseas like cancer hepat heart diseas
mani rare condit yet midst progress spend retail physician-administ medicin
continu repres overal health care spend next decad mani new medicin
revolution care patient yet spend medicin project continu remain small stabl
share health care spend occur market-bas system unit state promot
incent continu innov increas patient access need medicin leverag competit
control cost
 market highli competit robust competit brand gener andincreasinglybiosimilar
altern result medicin price fall dramat competit occur among brand name medicin
price fall even gener introduc market fact prescript fill patient
unit state gener typic cost fraction price initi brand medicin ix expect
dynam continu year ahead sinc billion brand sale project face gener
biosimilar competit
anoth reason current marketplac medicin success control cost health insur
pharmaci benefit manag pbm power sophist purchas use leverag negoti
discount rebat list price medicin today top three pbm manag
prescript fill unit state xi averag list price medicin given
rebat discount insur compani govern pbm entiti suppli chain often
requir larg rebat medicin cover xii fact evid suggest negoti discount rebat
price concess doubl sinc total billion
continu growth rebat discount keep prescript medicin price growth slowest rate
year doesnt feel way mani patient often negoti save make way
patient increasingli ask pay pocket innov medicin unlik care receiv
in-network hospit physician offic patient high deduct coinsur pay cost share base
list price medicin even though insur may receiv steep discount half commerci
insur patient out-of-pocket spend brand medicin base full list price xiv mean patient
high deduct health plan pay list price month medicin may pay hundredsor even
thousandsmor year insur pay medicin
insur increasingli expos patient list price medicin patient seen out-of-pocket cost
continu grow pharmaci commerci insur patient deduct seen out-of-pocket
cost brand medicin increas sinc
though rebat discount grown substanti health plan typic use portion negoti
rebat reduc premium enrolle rather directli lower cost patient face high cost-shar
due deduct coinsur creat system payer requir patient pay pocket
rebat save spread among health plan enrolle form lower premium ask sicker
patient subsid premium healthier enrolle exact opposit health insur suppos
chang need ensur billion negoti rebat discount price concess
use lower cost patient pharmaci counter research show high cost share associ
lower medic adher increas abandon rate put patient abil stay need
therapi risk share negoti discount could save certain commerci insur patient high deduct
coinsur annual increas premium less xx medicar
part polici ensur save negoti discount pass medicar beneficiari would also
improv afford senior strengthen competit incent part program exampl typic
medicar beneficiari diabet take five medicin could save year out-of-pocket cost
america biopharmaceut compani commit work policymak stakehold advanc
market-bas solut aim toward ensur patient access need treatment support continu
innov drive valu health care system address misalign suppli chain incent
statu quo work patient misalign incent health care system need chang
rebat price concess payer receiv biopharmaceut compani use lower
cost share patient pharmaci counter need improv afford predict
cost senior medicar part current limit out-of-pocket expens adopt out-
of-pocket cap medicar part would align benefit commerci insur market ensur
beneficiari face catastroph ill abl afford treatment provid patient
transpar medicin cost phrma member voluntarili direct patient link cost inform
direct-to-consum dtc televis advertis phrma also launch medicin assist tool
provid link referenc dtc televis advertis help patient connect financi assist
make medicin afford move toward health care system focus result measur
valu eye patient enabl privat sector develop new better way pay
medicin move toward value-driven health care system includ develop data provid
patient physician easy-to-us inform differ medicin work creation better measur
qualiti care take account patient feel reform allow new way insur pay
medicin advanc research method relat valu assess encompass outcom
matter patient famili import step toward goal
commit advanc market-bas reform promot competit modern drug discoveri
develop process get medicin approv effici ensur safeti need modern
drug discoveri develop process equip regul new technolog expertis keep
centuri scienc also need ensur time review approv gener biosimilar medicin
patient benefit less expens gener biosimilar medicin replac treatment follow expir
patent data protect addit unit state must continu incentiv medic innov
competit strong intellectu properti incent enforc within outsid unit
market-bas health care system work well control cost done help work even
better patient current system creat misalign incent pbm other suppli chain
favor medicin high list price rebat impact patient afford reform need
prevent pbm other suppli chain paid list price medicin instead fee base
valu servic provid wrong way address misalign incent greater govern
intervent marketplac negoti adopt harm practic countri restrict patient
access need medicin strengthen health care system must also address misalign profit incent
fuel hospit markup medicin provid consolid address misalign incent
present opportun reduc largest fastest contributor health care costshospit spend
pharmaceut research manufactur america phrma
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
